Teladoc, Inc. (NYSE:TDOC) has been assigned an average recommendation of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $37.30.

A number of equities research analysts recently commented on TDOC shares. Canaccord Genuity reissued a “buy” rating and issued a $34.00 price objective on shares of Teladoc in a research note on Wednesday, May 24th. Chardan Capital increased their price objective on shares of Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, June 20th. Robert W. Baird reissued a “buy” rating and issued a $28.00 price objective on shares of Teladoc in a research note on Tuesday, May 9th. Piper Jaffray Companies reissued a “buy” rating and issued a $32.00 price objective on shares of Teladoc in a research note on Friday, July 14th. Finally, TheStreet cut shares of Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/12/teladoc-inc-tdoc-receives-consensus-rating-of-buy-from-analysts.html.

Teladoc (NYSE:TDOC) opened at 30.35 on Friday. Teladoc has a 12-month low of $14.00 and a 12-month high of $36.90. The firm’s 50-day moving average is $33.88 and its 200 day moving average is $27.52. The stock’s market capitalization is $1.72 billion.

Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same period last year, the company earned ($0.38) earnings per share. The business’s revenue for the quarter was up 68.3% compared to the same quarter last year. Equities analysts expect that Teladoc will post ($1.47) EPS for the current year.

In other news, CEO Jason N. Gorevic sold 14,400 shares of the stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $29.57, for a total transaction of $425,808.00. Following the transaction, the chief executive officer now directly owns 822,961 shares in the company, valued at approximately $24,334,956.77. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 5,600 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $29.57, for a total transaction of $165,592.00. Following the transaction, the chief executive officer now owns 823,861 shares in the company, valued at $24,361,569.77. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 207,186 shares of company stock worth $6,122,950. Insiders own 5.94% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its stake in Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock worth $6,309,000 after buying an additional 9,146 shares during the period. Teachers Advisors LLC increased its stake in Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock worth $581,000 after buying an additional 1,759 shares during the period. First Mercantile Trust Co. acquired a new stake in Teladoc during the first quarter worth about $175,000. Russell Investments Group Ltd. acquired a new stake in Teladoc during the first quarter worth about $583,000. Finally, Wells Fargo & Company MN increased its stake in Teladoc by 43.8% in the first quarter. Wells Fargo & Company MN now owns 543,568 shares of the health services provider’s stock worth $13,589,000 after buying an additional 165,435 shares during the period. Institutional investors and hedge funds own 95.88% of the company’s stock.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.